Former Shire CEO shakes up Galderma as IPO decision looms
Flemming Ørnskov is "doubling down on science" and readying Galderma, formerly owned by Nestle, for competition with the likes of Sanofi.
by James Paton, bloomberg
Flemming Ørnskov led Shire's expansion into rare diseases before the drugmaker's USD 62bn (DKK 399.3bn) sale to Takeda Pharmaceutical Co. in 2019. Now he's plotting a new course for a skincare business that Nestle SA gave up on.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi's big dermatology hope fails in phase III
For subscribers
Sanofi pivots toward boosters after Covid vaccine delays
For subscribers
